Intuitive Surgical's valuation has become much more reasonable but is still a little too expensive with growth slowing. At its highs it traded at about 18x next-twelve-month revenue, which was nonsense. x.com 

Intuitive Surgical does not look cheap at the current price, contrary to the view that it is very tempting, though something could be missing. x.com 

Intuitive Surgical is a high-quality business near its 200-week moving average, the entry point Charlie Munger said would beat the S&P 500 by a wide margin over time. At the cutting edge of robotics and soon AI in healthcare, with no competition, very high barriers to entry and huge switching costs, it deserves a premium. At 34x forward earnings it is expensive but tolerable; about 30x is close to fair value, 25x is cheap and 20x a slam dunk. x.com  x.com  x.com 

Intuitive Surgical is worth 30 times earnings at most, below where it trades. Judged purely on its financials, without knowing what the company does, even 30 times would be too high. x.com 

Intuitive Surgical is a great company, but 13-15% growth will probably bring the stock under pressure. x.com 

Intuitive Surgical has fallen about 34% from its high and trades at 35x forward earnings, a drawdown that puts it on a list of names alongside Kinsale Capital. x.com 

Costco, Apple, Intuitive Surgical, Alphabet and MSCI are amazing companies priced too high for their growth. Costco trades at 46x earnings on high-single-digit growth, Apple at 32x forward on low-double-digit EPS growth, and Intuitive Surgical at 38x forward on low-teens growth. Alphabet, the most attractive, is 33x operating income excluding investment gains. MSCI is 34x trailing on low-double-digit growth; S&P Global is better, cheaper and extremely high quality with similar growth. x.com  … Show more

Boston Scientific looks cheap on an estimate-based cash-earnings screen: 13x current and 12x next year's cash earnings versus 14x for medical-device makers imply a $43.85-$55.81 fair range against $42.04. This is a levels-only comparison using reported estimates, not fundamental diligence. x.com 

Intuitive Surgical's share repurchases add capital return to its case as one of the highest-quality compounders in medical robotics. It bought back $4.45B of shares in the first nine months of 2026, including $2.94B in Q3, while kicking off an early Stage 2 uptrend after reclaiming its 200-day SMA. x.com 

Boston Scientific's extreme pessimism is already priced in after weaker-than-expected results destroyed the stock, leaving it at 11x 2027 earnings and creating a potential opportunity. The company makes medical devices, mainly for cardiology. x.com